Created in 2013 to capitalize on decades of expertise of drug developments in CNS, inflammation and oncology at Cephalon laboratories (TEVA group), CleveXel Pharma is a biotech company specializing in innovative treatments for neurodegenerative diseases and oncology.
CleveXel Pharma is currently developing a risk-balanced portfolio of drug programs ranging from lead optimization to clinical proof-of-concept.
Our lead product is a joint project with Gustave Roussy Institute, bringing an efficient and easy-to-use therapeutic solution to radiation-induced mucositis and radiation-induced dermatitis which are the most frequent and debilitating side effects of anti-cancer radiotherapy. Our innovative approach combines a clinically-established radical scavenger, a topical delivery system and a clinical mode of use elaborated together with radiotherapists to fit well with their medical practices. CVXL-0095 has demonstrated strong preclinical efficacy. As the drug substance is an authorized medication, IND-enabling program will be limited to local tolerance supporting a fast and direct entry into a Phase 2 proof-of-concept study.
CleveXel’s is willing to open its portfolio to partnership agreements, licensing or equity investment to speed-up and secure the advancement of the project, in a very open-minded approach.